Načítá se...
免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展
With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment...
Uloženo v:
| Vydáno v: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
中国肺癌杂志编辑部
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8143967/ https://ncbi.nlm.nih.gov/pubmed/33819969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.04 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|